Conference Call and Live Audio Webcast with Slide Presentation Scheduled for
May 10, 2017, 4:30 p.m. ET
CORALVILLE, Iowa, May 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical
company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference
call and live audio webcast on Wednesday, May 10, 2017, at 4:30 p.m. ET, to discuss its corporate and financial results for the
first quarter 2017.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 15162616
An audio webcast with slide presentation will be accessible via the Investor Relations section of the KemPharm website http://investors.kempharm.com/. An archive of the webcast and presentation will remain
available for 90 days beginning at approximately 5:30 p.m. ET, on May 10, 2017.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of
proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology.
KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of
pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical
development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an
acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For
more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 jrando@tiberend.com jdrumm@tiberend.com Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 dcohen@kempharm.com
